


Stämm is developing compact, continuous biomanufacturing systems for biologics and cell therapies.

Its mission is to **make bioprocesses easy, scalable, sustainable, and repeatable**, inspired by nature's solutions, unleashing the full potential of biotechnology and freeing partners to focus on the disruptive discoveries that impact people’s lives.


PROFILE

Sector: *Biotechnology*
Type of product: *Biomanufacturing solutions*
Foundation date: *2016*
People in the team: *200*




Yuyo Llamazares Vegh Co-founder & CEO

Lead inventor of the bioreactor technology & strong leader with expertise in disciplines including microbiology, synthetic biology, nanotechnology, and microfluidics.




Federico D’Alvia Vegh Co-founder & COO

10+ years of sales and market development and operations. He has successfully led five infrastructure expansions.




Juan Martín Cabaleiro, PhD. CTO

10+ years of scientific research in fluid dynamics, laser graving, 3D printing, and microfabrication.



Manuel del Cogliano, PhD. CSO

Microbiology, cellular, and molecular biology specialist.




Verona Llamazares Vegh CFO

12+ years of managing accounting, purchases, and budget, for national a branch of Shell.




Román Ortega Bianchi Head of BD

MBA with 10+ years experience in business development, sales & marketing strategy in the pharma industry in different countries.



Ignacio Campanelli Head of Product

Industrial designer. Co-inventor of Stämm’s 3D printing technology and rendering software.



Martín Palazzo Head of Silico

7+ years of research in AI applications for biology and +10 years in the tech industry

Reinventing biomanufacturing by providing an alternative to the known biomass production processes.

Stämm’s structures its products and services in three segments:

BIOMANUFACTURING

Stämm’s core solution is a **continuous, bubble-free Bioprocessor**, a bio-manufacturing platform with a novel 3D-printed bioreactor that enhances yields, reduces costs and minimizes footprint and energy consumption.

Stämm's approach enables a scalable,energy-efficient solution that provides an ideal cell growth environment.



BIO AI

Stämm is developing a transomics platform that leverages in-silico methods through their Multi-omic Network Atlas (MoNA™) allowing it to **map the biomolecular behaviour of cells with its experimental ambient conditions**.

With MoNA, biotechnologists and molecular biologists will be able to reduce the uncertainty and risk during wet lab assay design, execution, and interpretation. Therefore, achieving high-precision biomolecular decision-making.

BIOENGINEERING

Stämm is developing **state-of-the-art devices for Cell Line Development** with automated cell engineering, clone outgrowth & screening for the production of biologics.

This is being done through a **Bioengineering Platform**, an engineering and sorting platform powered by a high-throughput automated system to streamline workflows, and a **Clone Selection Platform**, a specialized solution that automates clone selection and screening, monitoring the process to optimize clients’ pipelines.

Our Milestones

